Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

被引：218

作者：

Kerr, K. M. ^{[1
,2
]}

Bubendorf, L. ^{[3
]}

Edelman, M. J. ^{[4
]}

Marchetti, A. ^{[5
]}

Mok, T. ^{[6
]}

Novello, S. ^{[7
]}

O'Byrne, K. ^{[8
,9
]}

Stahel, R. ^{[10
]}

Peters, S. ^{[11
]}

Felip, E. ^{[12
]}

机构：

[1] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[2] Aberdeen Univ Med Sch, Aberdeen, Scotland

[3] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland

[4] Univ New Mexico Canc Ctr, Albuquerque, NM USA

[5] Univ Fdn, Ctr Predict Mol Med, Ctr Excellence Ageing, Chieti, Italy

[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[7] Univ Turin, Azienda Osped Univ San Luigi Orbassano, Dept Oncol, Thorac Oncol Unit, I-10124 Turin, Italy

[8] Trinity Coll Dublin, Dublin, Ireland

[9] Queensland Univ Technol, Brisbane, Qld 4001, Australia

[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland

[11] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[12] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 09期

关键词：

ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations; MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; EXTERNAL QUALITY ASSESSMENT; FACTOR RECEPTOR MUTATIONS; ALK GENE REARRANGEMENTS; EML4-ALK FUSION GENE; PHASE-III TRIAL; BRONCHIAL BIOPSY; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL CLASSIFICATION;

D O I：

10.1093/annonc/mdu145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

引用

页码：1681 / 1690

页数：10

共 50 条

[41] Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways
Borczuk, AC
Gorenstein, L
Walter, KL
Assaad, AA
Wang, LQ
Powell, CA
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05): : 1949 - 1960
[42] Avelumab in non-small-cell lung cancer
Rosell, Rafael
Karachaliou, Niki
LANCET ONCOLOGY, 2018, 19 (11): : 1423 - 1424
[43] Radiochemotherapy in non-small-cell lung cancer
Swartman, B.
Hausmanns, J.
Zwicker, F.
Thomas, M.
Herfarth, K.
Heussel, C. P.
MEDIZINISCHE KLINIK, 2011, 106 (03) : 212 - 217
[44] Cetuximab in non-small-cell lung cancer
Carillio, Guido
Montanino, Agnese
Costanzo, Raffaele
Sandomenico, Claudia
Piccirillo, Maria Carmela
Di Maio, Massimo
Daniele, Gennaro
Giordano, Pasqualina
Bryce, Jane
Normanno, Nicola
Rocco, Gaetano
Perrone, Francesco
Morabito, Alessandro
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
[45] Non-small-cell lung cancer in the elderly
Meriggi, F
Zaniboni, A
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190
[46] Immunotherapy for non-small-cell lung cancer
Thomas, Anish
Jakopovic, Marko
EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
[47] Staging of Non-Small-Cell Lung Cancer
Akhurst, Tim
PET CLINICS, 2018, 13 (01) : 1 - +
[48] LncRNAs in Non-Small-Cell Lung Cancer
Ginn, Lucy
Shi, Lei
La Montagna, Manuela
Garofalo, Michela
NON-CODING RNA, 2020, 6 (03)
[49] Osimertinib for non-small-cell Lung Cancer
Alakus, Hakan
Zander, Thomas
Bruns, Christiane
ONKOLOGE, 2018, 24 (02): : 174 - 176
[50] Adagrasib in Non-Small-Cell Lung Cancer
Kotecha, Rupesh
Sahgal, Arjun
Mehta, Minesh P.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (13): : 1238 - 1239

← 1 2 3 4 5 →